Intensive Care Unit Mortality Trends during the First Two Years of the COVID-19 Pandemic in Greece: A Multi-Center Retrospective Study
Authors:
- Paraskevi C. FragkouParaskevi C. Fragkou
- Sotirios P. KaragiannisSKSotirios P. Karagiannis
- Dimitra DimopoulouDDDimitra Dimopoulou
- Sotiria KefalaSKSotiria Kefala
- Fotini FligouFFFotini Fligou
- Parisis GallosParisis Gallos
- Edison JahajEJEdison Jahaj
- Angeliki BellouABAngeliki Bellou
- Evangelia KoukakiEKEvangelia Koukaki
- Eleni MagiraEMEleni Magira
- Philippos OrfanosPOPhilippos Orfanos
- Georgios PapathanakosGPGeorgios Papathanakos
Open Access
Abstract
Data on COVID-19 mortality among patients in intensive care units (ICUs) from Eastern and/or Southern European countries, including Greece, are limited. The purpose of this study was to evaluate the ICU mortality trends among critically ill COVID-19 patients during the first two years of the pandemic in Greece and to further investigate if certain patients’ clinical characteristics contributed to this outcome. We conducted a multi-center retrospective observational study among five large university hospitals in Greece, between February 2020 and January 2022. All adult critically ill patients with confirmed COVID-19 disease who required ICU admission for at least 24 h were eligible. In total, 1462 patients (66.35% males) were included in this study. The mean age of this cohort was 64.9 (±13.27) years old. The 28-day mortality rate was 35.99% (n = 528), while the overall in-hospital mortality was 50.96% (n = 745). Cox regression analysis demonstrated that older age (≥65 years old), a body mass index within the normal range, and a delay in ICU admission from symptom onset, as well as worse baseline clinical severity scores upon ICU admission, were associated with a greater risk of death. Mortality of critically ill COVID-19 patients was high during the first two years of the pandemic in Greece but comparable to other countries. Risk factors for death presented in this study are not different from those that have already been described for COVID-19 in other studies.Keywords
This publication has 22 references indexed in Scilit:
- Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort studyThe Lancet Infectious Diseases, 2023
- Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical TrialJAMA, 2023
- Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesThe Lancet, 2022
- Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21The Lancet, 2022
- Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort studyThe Lancet Infectious Diseases, 2022
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionNature, 2021
- Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort studyIntensive Care Medicine, 2020
- COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern IrelandIntensive Care Medicine, 2020
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, ItalyJAMA Internal Medicine, 2020
- Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohorteClinicalMedicine, 2020